litlas
Log inCreate account

Bo Åhrén

Active 1979–2025

Also published as
Bo Ahrén
166
Papers
29,416
Citations
104
h-index
165
i10-index

Citations

Citations per year for Bo Åhrén1982: 3 citations1983: 2 citations1984: 3 citations1985: 3 citations1986: 7 citations1987: 17 citations1988: 11 citations1989: 14 citations1990: 7 citations1991: 4 citations1992: 14 citations1993: 18 citations1994: 20 citations1995: 30 citations1996: 18 citations1997: 40 citations1998: 81 citations1999: 78 citations2000: 116 citations2001: 127 citations2002: 186 citations2003: 222 citations2004: 336 citations2005: 324 citations2006: 341 citations2007: 378 citations2008: 363 citations2009: 355 citations2010: 305 citations2011: 336 citations2012: 286 citations2013: 307 citations2014: 311 citations2015: 287 citations2016: 239 citations2017: 186 citations2018: 224 citations2019: 690 citations2020: 593 citations2021: 594 citations2022: 473 citations2023: 323 citations2024: 475 citations2025: 265 citations2026: 9 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,694 citing papers, 25.4% of this breakdownUnited Kingdom: 712 citing papers, 6.7% of this breakdownChina: 606 citing papers, 5.7% of this breakdownGermany: 589 citing papers, 5.5% of this breakdownDenmark: 570 citing papers, 5.4% of this breakdownSweden: 551 citing papers, 5.2% of this breakdownCanada: 505 citing papers, 4.8% of this breakdownItaly: 467 citing papers, 4.4% of this breakdownJapan: 333 citing papers, 3.1% of this breakdownFrance: 332 citing papers, 3.1% of this breakdownAustralia: 323 citing papers, 3% of this breakdownSpain: 282 citing papers, 2.7% of this breakdown
0%25.4%Other 25%

Institutions

Fields

  • Medicine71%
  • Neuroscience12.7%
  • Biochemistry, Genetics and Molecular Biology11%
  • Nursing1.6%
  • Immunology and Microbiology0.8%
  • Agricultural and Biological Sciences0.6%
  • Other2.3%

Topics

  • Diabetes Treatment and Management10.1%
  • Pancreatic function and diabetes7.8%
  • Regulation of Appetite and Obesity4.8%
  • Adipose Tissue and Metabolism4.7%
  • Adipokines, Inflammation, and Metabolic Diseases3.9%
  • Metabolism, Diabetes, and Cancer3.7%
  • Other65%

Coauthors

All papers

Open in search
  1. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

    Authors: Bo Åhrén, Luís Masmiquel, Harish Kumar, Mehmet Sargın, Julie Derving Karsbøl, Sanja Hald Jacobsen, Francis Chun Chung Chow - The Lancet Diabetes & Endocrinology 2017 cited by 476

  2. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial

    Authors: Bo Åhrén, Irl B. Hirsch, Thomas R. Pieber, Chantal Mathieu, Fernando Gómez‐Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jensen, John B. Buse, for the ADJUNCT TWO Investigators - Diabetes Care 2016 cited by 251

  3. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

    Authors: Bo Åhrén, Stephen L. Atkin, G. Charpentier, Mark Warren, John Wilding, Sune Birch, Anders G. Holst, Lawrence A. Leiter - Diabetes Obesity and Metabolism 2018 cited by 152

  4. The High-Fat Diet–Fed Mouse

    Authors: Maria Sörhede Winzell, Bo Åhrén - Diabetes 2004 cited by 1,016

  5. Interleukin-6-deficient mice develop mature-onset obesity

    Authors: Ville Wallenius, Kristina Wallenius, Bo Åhrén, Mats Rudling, Hans Carlsten, Suzanne L. Dickson, Claes Ohlsson, John‐Olov Jansson - Nature Medicine 2002 cited by 1,212

  6. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy

    Authors: Matthias H. Tschöp, Rubén Nogueiras, Bo Åhrén - Diabetologia 2023 cited by 86

  7. Glucose-dependent insulinotropic polypeptide (GIP)

    Authors: Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, Matthias Blüher, Andreas L. Birkenfeld, Jonathan E. Campbell, Matthew P. Coghlan, David D’Alessio, Carolyn F. Deacon, Stefano DelPrato, Jonathan D. Douros, Daniel J. Drucker, N. Burgos, Peter R. Flatt, Brian Finan, Ruth E. Gimeno, Fiona M. Gribble, Matthew R. Hayes, Christian Hölscher, Jens J. Holst, Patrick J. Knerr, Filip K. Knop, Christine M. Kusminski, Arkadiusz Liśkiewicz, Guillaume Mabilleau, Stephanie A. Mowery, Michael A. Nauck, Aaron Novikoff, Frank Reimann, Anna G Roberts, Mette M. Rosenkilde, Ricardo J. Samms, Philip E Scherer, Randy J. Seeley, Kyle W. Sloop, Christian Wolfrum, Denise Wootten, Richard D. DiMarchi, Matthias H. Tschöp - Molecular Metabolism 2025 cited by 61

  8. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

    Authors: Thomas Nyström, M. Gutniak, Qimin Zhang, Fan Zhang, Jens J. Holst, Bo Åhrén, Åke Sjöholm - American Journal of Physiology-Endocrinology and Metabolism 2004 cited by 671

  9. Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation

    Authors: Kristine Færch, Dorte Vistisen, Giovanni Pacini, Signe S. Torekov, Nanna B. Johansen, Daniel R. Witte, Anna Jonsson, Oluf Pedersen, Torben Hansen, Torsten Lauritzen, Marit E. Jørgensen, Bo Åhrén, Jens J. Holst - Diabetes 2016 cited by 229

  10. Autonomic regulation of islet hormone secretion - Implications for health and disease

    Authors: Bo Åhrén - Diabetologia 2000 cited by 900

  11. Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes Mellitus

    Authors: M. Gutniak, Cathrine Ørkov, Jens J. Holst, Bo Åhrén, Suad Efendić - New England Journal of Medicine 1992 cited by 875

  12. Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial

    Authors: Daniela Jakubowicz, Julio Wainstein, Zohar Landau, Itamar Raz, Bo Åhrén, Nava Chapnik, Tali Ganz, Miriam Menaged, Maayan Barnea, Yosefa Bar‐Dayan, Oren Froy - Diabetes Care 2017 cited by 176

  13. Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)

    Authors: Bo Åhrén, Aniceto Leguizamo Dimas, P. Miossec, Stéphane Saubadu, Ronnie Aronson - Diabetes Care 2013 cited by 171

  14. Evidence that oestrogen receptor-α plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver

    Authors: Galyna Bryzgalova, Hui Gao, Bo Åhrén, Juleen R. Zierath, Dana Galuska, Tatiana L. Steiler, Karin Dahlman‐Wright, S. Nilsson, Jan Gustafsson, Suad Efendić, Abdul Waheed Khan - Diabetologia 2006 cited by 378

  15. HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

    Authors: Bo Åhrén, Susan Johnson, Murray Stewart, Deborah T. Cirkel, Fred Yang, Caroline Perry, Mark N. Feinglos - Diabetes Care 2014 cited by 226

  16. Surrogate measures of insulin sensitivity vs the hyperinsulinaemic–euglycaemic clamp: a meta-analysis

    Authors: Julia Otten, Bo Åhrén, Tommy Olsson - Diabetologia 2014 cited by 168

  17. High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial

    Authors: Daniela Jakubowicz, Julio Wainstein, Bo Åhrén, Yosefa Bar‐Dayan, Zohar Landau, Hadas Rachel Rabinovitz, Oren Froy - Diabetologia 2015 cited by 138

  18. DPP-4 inhibitors

    Authors: Bo Åhrén - Best Practice & Research Clinical Endocrinology & Metabolism 2007 cited by 203

  19. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

    Authors: Bo Åhrén - Nature Reviews Drug Discovery 2009 cited by 419

  20. Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

    Authors: Julio Rosenstock, Vivian Fonseca, Jorge Luiz Gross, Robert E. Ratner, Bo Åhrén, Francis C. C. Chow, Fred Yang, Diane Miller, Susan Johnson, Murray Stewart, Lawrence A. Leiter - Diabetes Care 2014 cited by 205

  21. Differential Islet and Incretin Hormone Responses in MorningVersusAfternoon after Standardized Meal in Healthy Men

    Authors: Ola Lindgren, Andrea Mari, Carolyn F. Deacon, Richard D. Carr, Maria Sörhede Winzell, Jenny Vikman, Bo Åhrén - The Journal of Clinical Endocrinology & Metabolism 2009 cited by 109

  22. Islet Amyloid and Type 2 Diabetes Mellitus

    Authors: Jo W.M. Höppener, Bo Åhrén, Cornelis J.M. Lips - New England Journal of Medicine 2000 cited by 526

  23. Fasting Until Noon Triggers Increased Postprandial Hyperglycemia and Impaired Insulin Response After Lunch and Dinner in Individuals With Type 2 Diabetes: A Randomized Clinical Trial

    Authors: Daniela Jakubowicz, Julio Wainstein, Bo Åhrén, Zohar Landau, Yosefa Bar‐Dayan, Oren Froy - Diabetes Care 2015 cited by 167

  24. Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials

    Authors: Matteo Monami, Bo Åhrén, Ilaria Dicembrini, Edoardo Mannucci - Diabetes Obesity and Metabolism 2012 cited by 256